{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-028522","form_type":"8-K","ticker":"CING","cik":"0001862150","company_name":"Cingulate Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.866175+00:00","generated_at":"2026-06-11T12:51:50.318512+00:00","sec_items":["1.01","2.02","3.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cingulate Q2 cash $0.3M, net loss widens to $6.6M; Phase 3 adult ADHD trial misses primary endpoint","bullets":["Cash and equivalents $0.3M at June 30, 2023; expects to fund operations only into September 2023.","Net loss $6.6M in Q2 2023 vs $4.0M in Q2 2022; R&D expenses $4.5M vs $2.2M.","Phase 3 adult efficacy trial of CTx-1301 did not achieve statistical significance on primary endpoint; effect size 1.79 cited.","Private placement with WFIA: 1,823,155 shares at $0.5485, gross proceeds $1.0M, closed August 11, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-028522","json":"https://secwatch.observer/filing/0001493152-23-028522.json","markdown":"https://secwatch.observer/filing/0001493152-23-028522.md","text":"https://secwatch.observer/filing/0001493152-23-028522.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1862150/000149315223028522/0001493152-23-028522-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1862150/000149315223028522/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T12:51:50.318512+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bf709c6db839293d3be313630e02e40396e668e1","claim":"Cingulate Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"On August 14, 2023, the Company issued a press release announcing its financial results for the second quarter of 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315223028522/0001493152-23-028522-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"6be34dc282fb9d20313ad896d31c15fc3a4cfff0","claim":"Cingulate Inc. entered into Securities Purchase Agreement with Werth Family Investment Associates LLC valued at aggregate gross proceeds to the Company of approximately $1.0 million (effective 2023-08-11).","evidence_excerpt":"On August 11, 2023, Cingulate Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with Werth Family Investment Associates LLC (“WFIA”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1862150/000149315223028522/0001493152-23-028522-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Werth Family Investment Associates LLC"},{"label":"Value","value":"aggregate gross proceeds to the Company of approximately $1.0 million"},{"label":"Effective","value":"2023-08-11"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}